{
    "clinical_study": {
        "@rank": "107508", 
        "acronym": "ANGIOMET", 
        "arm_group": {
            "arm_group_label": "Paclitaxel, carboplatin and bevacizumab", 
            "description": "Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression"
        }, 
        "brief_summary": {
            "textblock": "This is a pharmacogenomic study with carboplatin, paclitaxel and bevacizumab as first line\n      therapy in patients with non-squamous advanced non-small cell lung cancer."
        }, 
        "brief_title": "Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Nonsquamous Nonsmall Cell Neoplasm of Lung", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a observational study prospectively followed post-authorization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients should sign inform consent before inclusion in the study that specifies that\n             the clinical treatment entails consent for the analysis of biological samples of\n             tumor and blood.\n\n          2. Histologically confirmed diagnosis of advanced non small-cell lung carcinoma,\n             non-squamous cell\n\n          3. Patients age 18 years or more\n\n          4. Patients will be candidates to received a first line of chemotherapy of carboplatin,\n             paclitaxel and bevacizumab as the best therapeutic option.\n\n          5. Evidence of measurable disease per Response Evalutation Criteria in Solid tumors\n             (RECIST)\n\n          6. Patients must be avalaible for clinical follow-up\n\n          7. Patients with the following hematologic/biochemical values:\n\n               -  Absolute Neutrophil Count ANC > 1500/\u00b5l.\n\n               -  Platelets > 100.000 /\u00b5l.\n\n               -  Hemoglobine  > 10 g/dl.\n\n               -  Bilirrubin < 1.5 mg/dl.\n\n               -  Aspartate aminotransfereasa (AST) and Alanine transaminase (ALT) \u2264 3 x LSN,\n                  except in case of hepatic metastases: upper 5 x LSN\n\n               -  Creatinine clearance \u2265 45 ml/min.\n\n        Exclusion Criteria:\n\n          1. Previous treatment for advanced disease. Chemotherapy is allowed if the initial\n             diagnosis of the patient is limited disease and the patient has received adjuvant or\n             neadjuvant treatment\n\n          2. history of haemoptysis (defined as at least half a teaspoon's emission of red blood)\n             in the 3 months prior to inclusion\n\n          3. evidence by CT of tumor cavitations, or tumours invading or abutting major blood\n             vessels\n\n          4. Known or suspected brain metastases non-treated.\n\n          5. Major surgery within 28 days of starting treatment.\n\n          6. Minor surgery within 24 hours before starting the treatment.\n\n          7. Non-controlled hypertension  (systolic > 150 mm Hg and/or diastolic > 100 mm Hg).\n\n          8. Patients with coronary disease or uncontrolled arrhytmia, uncontrolled\n             cerebrovascular disease and other clinical conditions that, in judgment of the\n             investigator, contraindicate the patient's participation in the study.\n\n          9. History or evidence of bleeding diathesis or hereditary coagulopathy.\n\n         10. Contraindication or suspected allergy to the products under investigation in the\n             study:: paclitaxel, carboplatine or bevacizumab.\n\n         11. Patients who are pregnant or breasfeeding. Women of childbearing potencial must have\n             a negative pregnancy test performed within 7 days before the onset of treatment.\n\n         12. Substance abuse of clinical, psychological or social conditions that can undermine\n             the validity of the informed consent or protocol compliance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with non-small cell lung cancer advanced unresectable, metastatic or recurrent,\n        non-squamous and untreated with chemotherapy"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814163", 
            "org_study_id": "GECP 09-02"
        }, 
        "intervention": {
            "arm_group_label": "Paclitaxel, carboplatin and bevacizumab", 
            "description": "Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression", 
            "intervention_name": "paclitaxel, carboplatin and bevacizumab", 
            "intervention_type": "Drug", 
            "other_name": "Taxol, carboplatin, avastin"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Bevacizumab", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "First line treatment", 
            "Non small cell lung cancer, non squamous"
        ], 
        "lastchanged_date": "March 18, 2013", 
        "link": {
            "description": "Spanish Lung Cancer Group website", 
            "url": "http://www.gecp.org/"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Alicante", 
                        "country": "Spain"
                    }, 
                    "name": "H. Gen. Universitario Alicante"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Castell\u00f3n", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Provincial de Castell\u00f3n"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Elche (Alicante)", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital General de Elche"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "l'Hospitalet (Barcelona)", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital General de L'Hospitalet"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Palmas", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Insular Gran Canaria"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Gregorio Mara\u00f1on"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "H. Cl\u00ednico San Carlos"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "H. La Paz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Fundacion Jim\u00e9nez D\u00edaz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Cl\u00ednica Quir\u00f3n"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Majadahonda (Madrid)", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Puerta de Hierro"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain"
                    }, 
                    "name": "Clinica Rotger"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Son Espases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Cruz de Tenerife", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Ntra Sra Candelaria"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Cruz de Tenerife", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Canarias"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "H. Gen. Univ. Valencia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Dr. Peset"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital La Fe"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Arnau de Vilanova"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Miguel Servet"
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "1", 
        "official_title": "Observational Studies to Explore the Relation Between Angiogenic Markers and the Treatment Response With Carboplatin, Paclitaxel and Bevacizumab in First Line of Advanced Non-small-cell Lung Cancer With Non- Squamous Histology", 
        "overall_official": [
            {
                "affiliation": "H. Gen. Univ.Alicante", 
                "last_name": "Bartomeu Massut\u00ed, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "H. Gen. Univ. Valencia", 
                "last_name": "Carlos Camps, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "H. La Paz", 
                "last_name": "Javier de Castro, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Correlation between angiogenesis markers and progression free survival.", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814163"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overal survival", 
                "safety_issue": "No", 
                "time_frame": "3 year"
            }, 
            {
                "measure": "Survival at 12 and 24 months", 
                "safety_issue": "No", 
                "time_frame": "12-24 months"
            }, 
            {
                "measure": "Objective response", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Treatment security", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Spanish Lung Cancer Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spanish Lung Cancer Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2013"
    }
}